Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 244

1.

Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study.

Aucella F, Maas R, Vigilante M, Tripepi G, Schwedhelm E, Margaglione M, Gesualdo L, Boeger R, Zoccali C.

Atherosclerosis. 2009 Dec;207(2):541-5. doi: 10.1016/j.atherosclerosis.2009.05.011. Epub 2009 May 21.

PMID:
19501358
3.

Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study.

Siegerink B, Maas R, Vossen CY, Schwedhelm E, Koenig W, Böger R, Rothenbacher D, Brenner H, Breitling LP.

Clin Res Cardiol. 2013 Mar;102(3):193-202. doi: 10.1007/s00392-012-0515-4. Epub 2012 Oct 17.

PMID:
23073705
4.

Dimethylarginine levels and nutritional status in hemodialysis patients.

Cupisti A, Saba A, D'Alessandro C, Meola M, Panicucci E, Panichi V, Raffaelli A, Barsotti G.

J Nephrol. 2009 Sep-Oct;22(5):623-9.

PMID:
19809995
5.

Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients.

Fleck C, Janz A, Schweitzer F, Karge E, Schwertfeger M, Stein G.

Kidney Int Suppl. 2001 Feb;78:S14-8.

PMID:
11168976
6.

Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach.

Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C.

J Am Soc Nephrol. 2005 Aug;16(8):2449-55. Epub 2005 Jun 8.

7.

Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition.

Wang Z, Tang WH, Cho L, Brennan DM, Hazen SL.

Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1383-91. doi: 10.1161/ATVBAHA.109.185645. Epub 2009 Jun 18.

8.

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R.

Lancet. 2001 Dec 22-29;358(9299):2113-7.

PMID:
11784625
9.

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

Schulze F, Carter AM, Schwedhelm E, Ajjan R, Maas R, von Holten RA, Atzler D, Grant PJ, Böger RH.

Atherosclerosis. 2010 Feb;208(2):518-23. doi: 10.1016/j.atherosclerosis.2009.06.039. Epub 2009 Jul 23.

PMID:
19700158
10.

Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases.

Fleck C, Schweitzer F, Karge E, Busch M, Stein G.

Clin Chim Acta. 2003 Oct;336(1-2):1-12. Review.

PMID:
14500028
11.

Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients.

Tripepi G, Mattace Raso F, Sijbrands E, Seck MS, Maas R, Boger R, Witteman J, Rapisarda F, Malatino L, Mallamaci F, Zoccali C.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1714-21. doi: 10.2215/CJN.11291210. Epub 2011 Jun 3.

12.

Circulating levels of dimethylarginines, chronic kidney disease and long-term clinical outcome in non-ST-elevation myocardial infarction.

Cavalca V, Veglia F, Squellerio I, De Metrio M, Rubino M, Porro B, Moltrasio M, Tremoli E, Marenzi G.

PLoS One. 2012;7(11):e48499. doi: 10.1371/journal.pone.0048499. Epub 2012 Nov 19.

13.

Symmetric dimethylarginine is a marker of detrimental outcome in the acute phase after ischaemic stroke: role of renal function.

Lüneburg N, von Holten RA, Töpper RF, Schwedhelm E, Maas R, Böger RH.

Clin Sci (Lond). 2012 Feb;122(3):105-11. doi: 10.1042/CS20110013.

PMID:
21777201
14.

Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure.

MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E.

Nephrol Dial Transplant. 1996 Dec;11(12):2449-52.

PMID:
9017621
15.

Association of homoarginine and methylarginines with liver dysfunction and mortality in chronic liver disease.

Pilz S, Putz-Bankuti C, Meinitzer A, März W, Kienreich K, Stojakovic T, Pieber TR, Stauber RE.

Amino Acids. 2015 Sep;47(9):1817-26. doi: 10.1007/s00726-015-2000-7. Epub 2015 May 8.

PMID:
25952253
16.

Symmetric dimethylarginine is an independent predictor of intradialytic hypotension.

Mangoni AA, Hewitson CL, Woodman RJ, Whiting MJ, McAteer-Carr B, Barbara JA.

Am J Hypertens. 2008 Aug;21(8):955-9. doi: 10.1038/ajh.2008.214. Epub 2008 Jun 12.

PMID:
18551101
17.

Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease.

Hov GG, Aasarød KI, Sagen E, Åsberg A.

Clin Biochem. 2015 Jul;48(10-11):646-51. doi: 10.1016/j.clinbiochem.2015.03.012. Epub 2015 Mar 28.

PMID:
25828044
18.

Symmetrical dimethylarginine predicts mortality in the general population: observations from the Dallas heart study.

Gore MO, Lüneburg N, Schwedhelm E, Ayers CR, Anderssohn M, Khera A, Atzler D, de Lemos JA, Grant PJ, McGuire DK, Böger RH.

Arterioscler Thromb Vasc Biol. 2013 Nov;33(11):2682-8. doi: 10.1161/ATVBAHA.113.301219. Epub 2013 Sep 5.

19.

The effect of n-3 fatty acids on levels of methylarginines in patients with end-stage renal disease.

Svensson M, Frøbert O, Schmidt EB, Jørgensen KA, Simonsen U, Christensen JH.

J Nephrol. 2010 Jul-Aug;23(4):459-64.

PMID:
20349405
20.

Increased levels of symmetric dimethyl-arginine are associated with all-cause mortality in patients with symptomatic peripheral arterial disease.

Staniszewska A, Rajagopalan S, Al-Shaheen A, Thies F, Brittenden J.

J Vasc Surg. 2015 May;61(5):1292-8. doi: 10.1016/j.jvs.2015.01.002. Epub 2015 Mar 13.

Supplemental Content

Support Center